<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies<sup>a</sup> or Predicted Interactions</caption>
<col width="25%"></col>
<col width="25%"></col>
<col width="50%"></col>
<thead>
<tr>
<th align="left" stylecode="Botrule Toprule " valign="bottom">
<content stylecode="bold">Concomitant Drug Class:<br/>Specific Drugs</content>
</th>
<th align="center" stylecode="Botrule Toprule " valign="bottom">
<content stylecode="bold">Effect on Concentration</content>
</th>
<th align="center" stylecode="Botrule Toprule " valign="bottom">
<content stylecode="bold">Clinical Comment</content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">
<sup>a</sup>  For magnitude of interactions see <content stylecode="emphasis">
<content stylecode="italics">
<linkhtml href="#ID_e6151d43-f4b5-4cbf-be4c-d0d707090afd">Clinical Pharmacology, Table 7 (12.3)</linkhtml>
</content>
</content>.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td colspan="3" stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">HIV Antiretroviral Agents: Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs and NtRTIs)</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>didanosine buffered formulations<br/>enteric-coated (EC) capsules</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir<br/>↓ didanosine</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Coadministration of atazanavir with didanosine buffered tablets resulted in a marked decrease in atazanavir exposure (presumably due to the increase in gastric pH caused by buffers in the didanosine tablets). It is recommended that EVOTAZ be given with food 2 hours before or 1 hour after didanosine buffered formulations. Simultaneous administration of didanosine EC and atazanavir with food results in a decrease in didanosine exposure. Thus, EVOTAZ and didanosine EC should be administered at different times.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>tenofovir disoproxil fumarate</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir<br/>↑ tenofovir</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Patients receiving EVOTAZ and tenofovir should be monitored for tenofovir-associated adverse reactions <content stylecode="italics">[see <linkhtml href="#ID_c292da00-c03c-4a93-9f39-e80302c9f9e4">Warnings and Precautions (5.4)</linkhtml>]</content>.</paragraph>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">HIV Antiretroviral Agents: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>efavirenz</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir<br/>↓ cobicistat<br/>↔ efavirenz</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Coadministration of EVOTAZ with efavirenz is not recommended because it may result in a loss of therapeutic effect and development of resistance to atazanavir.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>etravirine</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir<br/>↓ cobicistat</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Coadministration of EVOTAZ with etravirine is not recommended because it may result in the loss of therapeutic effect and development of resistance to atazanavir.</paragraph>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">HIV Antiretroviral Agents: CCR5 Antagonist</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>maraviroc</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ maraviroc</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>When coadministering maraviroc and EVOTAZ, patients should receive maraviroc 150 mg twice daily.</paragraph>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">HIV Antiretroviral Agents: Protease Inhibitors</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>ritonavir or products containing ritonavir</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>↑ atazanavir</paragraph>
</td>
<td stylecode="Botrule ">
<paragraph>Coadministration of EVOTAZ and ritonavir or ritonavir-containing regimens is not recommended due to similar effects of cobicistat and ritonavir on CYP3A <content stylecode="italics">[see <linkhtml href="#ID_71bb9d22-1d54-41d2-ac37-490c1f4896da">Warnings and Precautions (5)</linkhtml>]</content>.</paragraph>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">HCV Antiviral Agents: Protease Inhibitors</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>boceprevir</paragraph>
<paragraph>telaprevir</paragraph>
<paragraph>simeprevir</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>atazanavir: <br/>effects unknown</paragraph>
<paragraph>boceprevir:<br/>effects unknown</paragraph>
<paragraph>telaprevir:<br/>effects unknown</paragraph>
<paragraph>↑ simeprevir</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>No drug interaction data are available. Coadministration of EVOTAZ with boceprevir, telaprevir, or simeprevir is not recommended.</paragraph>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Other Agents</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Antacids (please also see H<sub>2</sub>-receptor antagonists and proton-pump inhibitors below)</content>
</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>With concomitant use, administer a minimum of 2 hours apart.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule ">
<paragraph>
<content stylecode="italics">Antiarrhythmics:<br/>
</content>amiodarone, quinidine<br/>lidocaine (systemic),<br/>disopyramide, flecainide<br/>mexiletine, propafenone</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>↑ antiarrhythmics</paragraph>
</td>
<td stylecode="Toprule ">
<paragraph>Clinical monitoring is recommended upon coadministration with antiarrhythmics.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>digoxin</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>↑ digoxin</paragraph>
</td>
<td stylecode="Botrule ">
<paragraph>When coadministering EVOTAZ with digoxin, titrate the digoxin dose and monitor digoxin concentrations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Antibacterials (macrolide or ketolide antibiotics):<br/>
</content>clarithromycin<br/>erythromycin<br/>telithromycin</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ atazanavir<br/>↑ cobicistat<br/>↑ clarithromycin<br/>↑ erythromycin<br/>↑ telithromycin</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Consider alternative antibiotics. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Anticancer Agents:<br/>
</content>(e.g., dasatinib, nilotinib, vinblastine, vincristine)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ anticancer agents</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>A decrease in the dosage or an adjustment of the dosing interval of dasatinib or nilotinib may be necessary upon coadministration with EVOTAZ. Consult the dasatinib and nilotinib full prescribing information for dosing instructions.</paragraph>
<paragraph>For vincristine and vinblastine, monitor for hematologic or gastrointestinal side effects.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule ">
<paragraph>
<content stylecode="italics">Anticoagulant:</content>
</paragraph>
</td>
<td stylecode="Toprule "></td>
<td stylecode="Toprule "></td>
</tr>
<tr>
<td>
<paragraph>apixaban, rivaroxaban</paragraph>
</td>
<td align="center">
<paragraph>↑ apixaban<br/>↑ rivaroxaban</paragraph>
</td>
<td>
<paragraph>Concomitant use of apixaban or rivaroxaban and EVOTAZ is not recommended.</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>dabigatran etexilate </paragraph>
</td>
<td align="center">
<paragraph>↑ dabigatran</paragraph>
</td>
<td>
<paragraph>Concomitant use of dabigatran etexilate and EVOTAZ is not recommended in specific renal impairment groups for certain indications. Refer to the dabigatran prescribing information for dosing recommendations for dabigatran etexilate when coadministered with P-gp inhibitors.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>warfarin</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>warfarin:<br/>effect unknown</paragraph>
</td>
<td stylecode="Botrule ">
<paragraph>Monitor the International Normalized Ratio (INR) when coadministered with warfarin.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Anticonvulsants:</content>
</paragraph>
<paragraph>Anticonvulsants that induce CYP3A (e.g., carbamazepine, oxcarbazepine, phenytoin, phenobarbital)</paragraph>
<paragraph>phenytoin, phenobarbital</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir</paragraph>
<paragraph>↓ cobicistat</paragraph>
<paragraph>phenobarbital and</paragraph>
<paragraph>phenytoin:<br/>effects unknown</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Consider alternative anticonvulsant or antiretroviral therapy to avoid potential changes in exposures. If coadministration is necessary, monitor for lack or loss of virologic response.</paragraph>
<paragraph>
<br/>Monitoring of phenobarbital or phenytoin concentrations is recommended with coadministration.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule ">
<paragraph>Anticonvulsants that are metabolized by CYP3A (e.g., clonazepam, carbamazepine)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>↑ clonazepam</paragraph>
<paragraph>↑ carbamazepine</paragraph>
</td>
<td stylecode="Toprule ">
<paragraph>Clinical monitoring of anticonvulsants is recommended with EVOTAZ coadministration.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>Other anticonvulsants (e.g., lamotrigine)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>lamotrigine:<br/>effects unknown</paragraph>
</td>
<td stylecode="Botrule ">
<paragraph>Monitoring of lamotrigine concentrations is recommended with EVOTAZ coadministration.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Antidepressants:</content>
</paragraph>
<paragraph>Selective Serotonin Reuptake Inhibitors (SSRIs)<br/>(e.g., paroxetine)</paragraph>
<paragraph>Tricyclic Antidepressants (TCAs) (e.g., amitriptyline, desipramine, imipramine, nortriptyline)</paragraph>
<paragraph>Other Antidepressants<br/>(e.g., trazodone)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>SSRIs:<br/>effects unknown</paragraph>
<paragraph>
<br/>↑ TCAs</paragraph>
<paragraph>
<br/>
<br/>
<br/>↑ trazodone</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>When coadministering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response are recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule ">
<paragraph>
<content stylecode="italics">Antifungals:<br/>
</content>ketoconazole, itraconazole</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>
<br/>↑ atazanavir<br/>↑ cobicistat<br/>↑ ketoconazole<br/>↑ itraconazole</paragraph>
</td>
<td stylecode="Toprule ">
<paragraph>
<br/>Specific dosing recommendations are not available for coadministration of EVOTAZ with either itraconazole or ketoconazole.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>voriconazole</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>effects unknown</paragraph>
</td>
<td stylecode="Botrule ">
<paragraph>Coadministration with voriconazole is not recommended unless the benefit/risk assessment justifies the use of voriconazole.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Antigout:</content>
<content stylecode="emphasis">
<br/>colchicine</content>
</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>
<br/>↑ colchicine</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>
<br/>The coadministration of EVOTAZ with colchicine in patients with renal or hepatic impairment is contraindicated <content stylecode="italics">[see <linkhtml href="#ID_7c7ea211-1b65-4d79-aacb-0be0584a05ec">Contraindications (4)</linkhtml>]</content>.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Recommended dosage of colchicine when administered with EVOTAZ:</content>
</content>
</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Treatment of gout flares:</content>
</content>
</paragraph>
<paragraph>0.6 mg (1 tablet) for 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course should be repeated no earlier than 3 days.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Prophylaxis of gout flares:</content>
</content>
</paragraph>
<paragraph>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.</paragraph>
<paragraph>If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Treatment of familial Mediterranean fever (FMF):</content>
</content>
</paragraph>
<paragraph>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day). </paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Antimycobacterials:</content>
<br/>rifabutin</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>atazanavir:<br/>effect unknown</paragraph>
<paragraph>cobicistat:<br/>effect unknown</paragraph>
<paragraph>↑ rifabutin</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>A rifabutin dose reduction of up to 75% (e.g., 150 mg every other day or 3 times per week) is recommended. Increased monitoring for rifabutin-associated adverse reactions, including neutropenia and uveitis, is warranted.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Antipsychotics:<br/>
</content>quetiapine</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>
<br/>↑ quetiapine</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>
<br/>
<content stylecode="bold">
<content stylecode="italics">Initiation of EVOTAZ in patients taking quetiapine:</content>
</content>
</paragraph>
<paragraph>Consider alternative antiretroviral therapy to avoid increases in quetiapine exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Initiation of quetiapine in patients taking EVOTAZ:</content>
</content>
</paragraph>
<paragraph>Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Beta-Blockers:<br/>
</content>(e.g., metoprolol, carvedilol, timolol)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↔ atazanavir<br/>↑ beta-blockers</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Clinical monitoring is recommended when beta-blockers that are metabolized by CYP2D6 are coadministered with EVOTAZ.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Calcium channel blockers:<br/>
</content>(e.g., amlodipine, diltiazem, felodipine, nifedipine, and verapamil)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ calcium channel blocker</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Clinical monitoring is recommended for coadministration with calcium channel blockers metabolized by CYP3A. ECG monitoring is recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Corticosteroids (systemic):</content>
<br/>dexamethasone and other corticosteroids</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir<br/>↓ cobicistat</paragraph>
<paragraph>↑ corticosteroids</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Concomitant use with dexamethasone or other corticosteroids that induce CYP3A may result in loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir.</paragraph>
<paragraph>Alternative corticosteroids should be considered.</paragraph>
<paragraph>Coadministration with corticosteroids that are metabolized by CYP3A, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression. Consider the potential benefit of treatment versus the risk of systemic corticosteroid effects.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Endothelin receptor antagonists:<br/>
</content>bosentan</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir<br/>↓ cobicistat<br/>↑ bosentan</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Initiation of bosentan in patients taking EVOTAZ:</content>
</content>
</paragraph>
<paragraph>For patients who have been receiving EVOTAZ for at least 10 days, start bosentan at 62.5 mg once daily or every other day based on individual tolerability.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Initiation of EVOTAZ in patients taking bosentan:</content>
</content>
</paragraph>
<paragraph>Discontinue bosentan at least 36 hours before starting EVOTAZ. After at least 10 days following initiation of EVOTAZ, resume bosentan at 62.5 mg once daily or every other day based on individual tolerability.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Switching from atazanavir coadministered with ritonavir to EVOTAZ:</content>
</content>
</paragraph>
<paragraph>Maintain bosentan dose.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">H</content>2<content stylecode="italics">‑Receptor antagonists (H</content>2<content stylecode="italics">RA)</content>:<br/>(e.g., famotidine) </paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Coadministration of EVOTAZ with tenofovir DF and an H2RA in treatment-experienced patients is not recommended.</paragraph>
<paragraph>Administer EVOTAZ either at the same time or at a minimum of 10 hours after a dose of the H2RA. The dose of the H2RA should not exceed a dose comparable to famotidine 40 mg twice daily in treatment-naive patients or 20 mg twice daily in treatment-experienced patients.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">HMG-CoA reductase inhibitors:</content>
<br/>atorvastatin, fluvastatin, pravastatin, rosuvastatin</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ HMG-CoA reductase inhibitors</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>For HMG-CoA reductase inhibitors that are not contraindicated with EVOTAZ, start with the lowest recommended dose and titrate while monitoring for safety <content stylecode="italics">[see <linkhtml href="#ID_7c7ea211-1b65-4d79-aacb-0be0584a05ec">Contraindications (4)</linkhtml>]</content>. Rosuvastatin dose should not exceed 10 mg/day.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Hormonal contraceptives:</content>
<br/>(e.g., progestin/estrogen)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>progestin and estrogen: effects unknown</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>No data are available to make recommendations on the coadministration of EVOTAZ and oral or other hormonal contraceptives. Alternative nonhormonal forms of contraception should be considered.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Immunosuppressants:<br/>
</content>(e.g., cyclosporine, everolimus, sirolimus, tacrolimus)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ immunosuppressants</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with EVOTAZ.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Inhaled beta-agonist:<br/>
</content>salmeterol</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ salmeterol</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Coadministration with salmeterol is not recommended due to an increased risk of cardiovascular adverse reactions associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Inhaled/nasal steroids: <br/>
</content>budesonide, fluticasone and other inhaled or nasal steroids</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ corticosteroids</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Coadministration with inhaled or nasal corticosteroids that are metabolized by CYP3A is not recommended unless the potential benefit to the patient outweighs the risks. Consider alternative corticosteroids, particularly for long-term use.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Narcotic analgesics:<br/>
</content>For treatment of opioid dependence:</paragraph>
<paragraph>buprenorphine, naloxone, methadone</paragraph>
<paragraph>fentanyl</paragraph>
<paragraph>tramadol</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>buprenorphine or buprenorphine/naloxone: effects unknown</paragraph>
<paragraph>methadone: effects unknown</paragraph>
<paragraph>↑ fentanyl</paragraph>
<paragraph>↑ tramadol</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Initiation of buprenorphine, buprenorphine/naloxone or methadone in patients taking EVOTAZ:<br/>
</content>
</content>Carefully titrate the dose of buprenorphine, buprenorphine/naloxone or methadone to the desired effect; use the lowest feasible initial or maintenance dose.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Initiation of EVOTAZ in patients taking buprenorphine, buprenorphine/naloxone or methadone:<br/>
</content>
</content>A dose adjustment for buprenorphine, buprenorphine/naloxone or methadone may be needed. Monitor clinical signs and symptoms.</paragraph>
<paragraph>When EVOTAZ is coadministered with fentanyl, careful monitoring of therapeutic and adverse effects of fentanyl (including potentially fatal respiratory depression) is recommended.</paragraph>
<paragraph>When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Neuroleptics:</content>
<br/>(e.g., perphenazine, risperidone, thioridazine)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ neuroleptics</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>A decrease in the dose of neuroleptics that are metabolized by CYP3A or CYP2D6 may be needed when coadministered with EVOTAZ.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Phosphodiesterase-5 (PDE-5) inhibitors:</content>
<br/>avanafil, sildenafil, tadalafil, vardenafil</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↑ PDE-5 inhibitors</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>Coadministration with avanafil is not recommended because a safe and effective avanafil dosage regimen has not been established.</paragraph>
<paragraph>Coadministration with EVOTAZ may result in an increase in PDE-5 inhibitor-associated adverse reactions, including hypotension, syncope, visual disturbances, and priapism.</paragraph>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</content>
</content>
</paragraph>
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="underline">Sildenafil</content> when used for the treatment of pulmonary hypertension (PAH) is contraindicated with EVOTAZ <content stylecode="italics">[see <linkhtml href="#ID_7c7ea211-1b65-4d79-aacb-0be0584a05ec">Contraindications (4)</linkhtml>]</content>.</item>
<item>
<caption> </caption>
<content stylecode="underline">Tadalafil</content>: The following dose adjustments are recommended for the use of tadalafil with EVOTAZ:</item>
<item>
<caption> </caption>Initiation of tadalafil in patients taking EVOTAZ:</item>
</list>
<list listtype="unordered">
<item>
<caption>o</caption>For patients receiving EVOTAZ for at least one week, start tadalafil at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.</item>
<item>
<caption> </caption>Initiation of EVOTAZ in patients taking tadalafil:</item>
</list>
<list listtype="unordered">
<item>
<caption>o</caption>Avoid the use of tadalafil when starting EVOTAZ. Stop tadalafil at least 24 hours before starting EVOTAZ. At least one week after starting EVOTAZ, resume tadalafil at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.</item>
<item>
<caption> </caption>Patients switching from atazanavir coadministered with ritonavir to EVOTAZ:</item>
</list>
<list listtype="unordered">
<item>
<caption>o</caption>Maintain tadalafil dose.</item>
</list>
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Use of PDE-5 inhibitors for erectile dysfunction:</content>
</content>
</paragraph>
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="underline">Sildenafil</content>: Reduced dosage to 25 mg every 48 hours with increased monitoring for adverse reactions.</item>
<item>
<caption> </caption>
<content stylecode="underline">Tadalafil</content>: Reduced dosage to 10 mg every 72 hours with increased monitoring for adverse reactions.</item>
<item>
<caption> </caption>
<content stylecode="underline">Vardenafil</content>: Reduced dosage to no more than 2.5 mg every 72 hours with increased monitoring for adverse reactions.</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Proton-pump inhibitors (PPI): <br/>
</content>(e.g., omeprazole)</paragraph>
</td>
<td align="center" stylecode="Toprule Botrule ">
<paragraph>↓ atazanavir</paragraph>
</td>
<td stylecode="Toprule Botrule ">
<paragraph>In treatment-naive patients, administer EVOTAZ a minimum of 12 hours after administration of the PPI. The dose of the PPI should not exceed a dose comparable to omeprazole 20 mg daily.</paragraph>
<paragraph>In treatment-experienced patients, coadministration of EVOTAZ with PPI is not recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Toprule ">
<paragraph>
<content stylecode="italics">Sedatives/hypnotics:<br/>
</content>buspirone, diazepam, zolpidem, and parenterally administered midazolam</paragraph>
</td>
<td align="center" stylecode="Botrule Toprule ">
<paragraph>↑ sedatives/hypnotics</paragraph>
</td>
<td stylecode="Botrule Toprule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Parenterally administered midazolam:</content>
</content> Coadministration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.</paragraph>
<paragraph>
<content stylecode="bold">Concomitant use with oral midazolam and triazolam is contraindicated </content>
<content stylecode="italics">[see <linkhtml href="#ID_7c7ea211-1b65-4d79-aacb-0be0584a05ec">Contraindications (4)</linkhtml>]</content>.</paragraph>
<paragraph>With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.</paragraph>
</td>
</tr>
</tbody>
</table>